120.94
price up icon0.17%   0.20
after-market Dopo l'orario di chiusura: 121.00 0.06 +0.05%
loading
Precedente Chiudi:
$120.74
Aprire:
$120.415
Volume 24 ore:
5.40M
Relative Volume:
0.80
Capitalizzazione di mercato:
$150.06B
Reddito:
$28.80B
Utile/perdita netta:
$6.31B
Rapporto P/E:
24.06
EPS:
5.0273
Flusso di cassa netto:
$9.37B
1 W Prestazione:
-1.52%
1M Prestazione:
+6.40%
6M Prestazione:
+13.93%
1 anno Prestazione:
+36.22%
Intervallo 1D:
Value
$118.70
$121.14
Intervallo di 1 settimana:
Value
$118.70
$124.61
Portata 52W:
Value
$86.08
$124.61

Gilead Sciences Inc Stock (GILD) Company Profile

Name
Nome
Gilead Sciences Inc
Name
Telefono
(650) 574-3000
Name
Indirizzo
333 LAKESIDE DR, FOSTER CITY, CA
Name
Dipendente
17,600
Name
Cinguettio
@GileadSciences
Name
Prossima data di guadagno
2025-02-11
Name
Ultimi documenti SEC
Name
GILD's Discussions on Twitter

Confronta GILD con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - General icon
GILD
Gilead Sciences Inc
120.94 149.82B 28.80B 6.31B 9.37B 5.0273
Drug Manufacturers - General icon
LLY
Lilly Eli Co
825.45 736.03B 53.26B 13.80B -50.20M 15.08
Drug Manufacturers - General icon
JNJ
Johnson Johnson
190.40 463.72B 92.15B 25.12B 20.46B 10.36
Drug Manufacturers - General icon
ABBV
Abbvie Inc
227.99 403.22B 58.33B 3.73B 18.24B 2.1013
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
130.36 254.84B 53.40B 13.68B 16.89B 6.8864
Drug Manufacturers - General icon
MRK
Merck Co Inc
87.49 217.76B 63.43B 16.42B 14.72B 6.4861

Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-08-19 Aggiornamento Daiwa Securities Neutral → Outperform
2025-08-08 Aggiornamento Truist Hold → Buy
2025-07-25 Aggiornamento Needham Hold → Buy
2025-04-22 Ripresa Cantor Fitzgerald Overweight
2025-03-04 Reiterato Oppenheimer Outperform
2025-02-18 Aggiornamento Deutsche Bank Hold → Buy
2025-02-13 Aggiornamento DZ Bank Hold → Buy
2025-01-10 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2024-12-10 Ripresa BofA Securities Buy
2024-11-15 Iniziato Wolfe Research Outperform
2024-11-14 Iniziato Citigroup Buy
2024-11-08 Downgrade Maxim Group Buy → Hold
2024-10-21 Aggiornamento Leerink Partners Market Perform → Outperform
2024-10-17 Iniziato Bernstein Outperform
2024-10-07 Aggiornamento Wells Fargo Equal Weight → Overweight
2024-07-08 Aggiornamento Raymond James Mkt Perform → Outperform
2024-05-01 Reiterato Maxim Group Buy
2024-04-24 Aggiornamento HSBC Securities Reduce → Hold
2024-02-22 Downgrade Truist Buy → Hold
2023-11-09 Iniziato Deutsche Bank Hold
2023-09-08 Aggiornamento BofA Securities Neutral → Buy
2023-09-06 Iniziato HSBC Securities Reduce
2023-07-24 Reiterato Barclays Equal Weight
2023-05-16 Aggiornamento BMO Capital Markets Market Perform → Outperform
2023-04-28 Ripresa Piper Sandler Overweight
2023-01-03 Downgrade RBC Capital Mkts Outperform → Sector Perform
2022-12-13 Ripresa BofA Securities Neutral
2022-12-09 Downgrade DZ Bank Buy → Hold
2022-10-31 Aggiornamento Barclays Underweight → Equal Weight
2022-10-28 Reiterato BMO Capital Markets Market Perform
2022-10-28 Reiterato Cowen Outperform
2022-10-28 Reiterato JP Morgan Overweight
2022-10-28 Reiterato Jefferies Buy
2022-10-28 Aggiornamento Piper Sandler Neutral → Overweight
2022-10-28 Reiterato RBC Capital Mkts Outperform
2022-10-28 Aggiornamento Truist Hold → Buy
2022-10-28 Reiterato Wells Fargo Equal Weight
2022-10-04 Aggiornamento JP Morgan Neutral → Overweight
2022-07-13 Iniziato Cantor Fitzgerald Neutral
2022-05-23 Iniziato SVB Leerink Mkt Perform
2022-02-28 Downgrade BMO Capital Markets Outperform → Market Perform
2022-02-02 Reiterato BMO Capital Markets Outperform
2022-02-02 Reiterato BofA Securities Neutral
2022-02-02 Reiterato RBC Capital Mkts Outperform
2022-02-02 Reiterato Truist Hold
2022-02-02 Reiterato Wells Fargo Equal Weight
2022-01-28 Aggiornamento Argus Hold → Buy
2022-01-06 Downgrade Morgan Stanley Overweight → Equal-Weight
2021-12-09 Ripresa Wells Fargo Equal Weight
2021-12-06 Iniziato Goldman Neutral
2021-11-19 Aggiornamento BMO Capital Markets Market Perform → Outperform
2021-11-19 Ripresa Piper Sandler Neutral
2021-10-20 Ripresa Cowen Outperform
2021-07-30 Reiterato BMO Capital Markets Market Perform
2021-07-30 Reiterato RBC Capital Mkts Outperform
2021-04-01 Aggiornamento Bernstein Mkt Perform → Outperform
2021-03-30 Aggiornamento Redburn Neutral → Buy
2021-01-19 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2021-01-04 Aggiornamento Guggenheim Neutral → Buy
2020-11-03 Ripresa Morgan Stanley Equal-Weight
2020-10-28 Iniziato UBS Neutral
2020-09-30 Ripresa Jefferies Buy
2020-09-15 Aggiornamento Maxim Group Hold → Buy
2020-07-31 Reiterato Credit Suisse Neutral
2020-07-31 Reiterato Morgan Stanley Equal-Weight
2020-07-31 Reiterato Piper Sandler Overweight
2020-07-31 Reiterato RBC Capital Mkts Outperform
2020-07-31 Reiterato SunTrust Hold
2020-07-31 Reiterato Wells Fargo Equal Weight
2020-07-20 Aggiornamento Credit Suisse Underperform → Neutral
2020-06-03 Aggiornamento SVB Leerink Mkt Perform → Outperform
2020-05-26 Aggiornamento SunTrust Sell → Hold
2020-05-01 Downgrade JP Morgan Overweight → Neutral
2020-05-01 Downgrade Raymond James Outperform → Mkt Perform
2020-05-01 Downgrade SunTrust Hold → Sell
2020-04-27 Downgrade UBS Buy → Neutral
2020-04-20 Downgrade BMO Capital Markets Outperform → Market Perform
2020-04-20 Downgrade Wells Fargo Overweight → Equal Weight
2020-04-17 Downgrade CFRA Hold → Sell
Mostra tutto

Gilead Sciences Inc Borsa (GILD) Ultime notizie

pulisher
09:50 AM

Is Gilead Sciences Inc. (GIS) stock inflation resilientEarnings Beat & Accurate Entry and Exit Point Alerts - newser.com

09:50 AM
pulisher
Oct 24, 2025

Is Gilead Sciences Inc. stock cheap at current valuation2025 Valuation Update & Precise Buy Zone Identification - newser.com

Oct 24, 2025
pulisher
Oct 24, 2025

Will Gilead Sciences Inc. stock remain a Wall Street favorite2025 Support & Resistance & Free Technical Pattern Based Buy Signals - newser.com

Oct 24, 2025
pulisher
Oct 24, 2025

What To Expect From Gilead In Q3 2025 (NASDAQ:GILD) - Seeking Alpha

Oct 24, 2025
pulisher
Oct 24, 2025

Gilead Sciences patents new PI3Kα inhibitors - BioWorld MedTech

Oct 24, 2025
pulisher
Oct 24, 2025

Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta - BioSpace

Oct 24, 2025
pulisher
Oct 23, 2025

Precision Trading with Gilead Sciences Inc. (GILD) Risk Zones - news.stocktradersdaily.com

Oct 23, 2025
pulisher
Oct 23, 2025

TD Cowen Raises Price Target for Gilead Sciences (GILD) to $125 | GILD Stock News - GuruFocus

Oct 23, 2025
pulisher
Oct 23, 2025

Commentary: A breakthrough to prevent HIV shouldn’t break the bank - The Boston Globe

Oct 23, 2025
pulisher
Oct 23, 2025

Gilead Sciences Rallies 32% in 2025 Are Shares Trading Below Their True Value - Yahoo Finance

Oct 23, 2025
pulisher
Oct 23, 2025

Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy? - Yahoo Finance

Oct 23, 2025
pulisher
Oct 23, 2025

Wolfe Research Adjusts Gilead Sciences Price Target to $140 From $135, Maintains Outperform Rating - MarketScreener

Oct 23, 2025
pulisher
Oct 23, 2025

TD Cowen Adjusts Gilead Sciences Price Target to $125 From $115, Maintains Buy Rating - MarketScreener

Oct 23, 2025
pulisher
Oct 23, 2025

Gilead to present new data on Livdelzi for PBC at Liver Meeting 2025 - Investing.com

Oct 23, 2025
pulisher
Oct 23, 2025

Gilead to present liver disease data at AASLD conference - StreetInsider

Oct 23, 2025
pulisher
Oct 23, 2025

(Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta - Business Wire

Oct 23, 2025
pulisher
Oct 23, 2025

Using economic indicators to assess Gilead Sciences Inc. potentialJuly 2025 Trade Ideas & Smart Money Movement Alerts - newser.com

Oct 23, 2025
pulisher
Oct 22, 2025

Gilead Sciences (GILD) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance

Oct 22, 2025
pulisher
Oct 22, 2025

CVS (CVS) Delays Adding Gilead's Yeztugo Over Pricing Concerns - GuruFocus

Oct 22, 2025
pulisher
Oct 22, 2025

Gilead Sciences (GILD) Halts Phase 1 HIV Treatment Trial - GuruFocus

Oct 22, 2025
pulisher
Oct 22, 2025

Gilead discontinues early-stage trial for long-acting injectable for HIV - Seeking Alpha

Oct 22, 2025
pulisher
Oct 22, 2025

Gilead Sciences stock rating reiterated by RBC amid HIV drug setback - Investing.com

Oct 22, 2025
pulisher
Oct 22, 2025

Gilead Sciences (GILD) Halts Phase 1 Study for HIV Treatment - GuruFocus

Oct 22, 2025
pulisher
Oct 22, 2025

CVS Caremark tells AIDS activists Gilead needs to lower the price of its new HIV drug to get on formularies - statnews.com

Oct 22, 2025
pulisher
Oct 22, 2025

What to Expect From Gilead Sciences' Next Quarterly Earnings Report - Yahoo Finance

Oct 22, 2025
pulisher
Oct 22, 2025

Exit strategy if you’re trapped in Gilead Sciences Inc.Quarterly Investment Review & Low Risk Investment Opportunities - newser.com

Oct 22, 2025
pulisher
Oct 22, 2025

Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia - GlobeNewswire Inc.

Oct 22, 2025
pulisher
Oct 22, 2025

How to build a dashboard for Gilead Sciences Inc. stockJuly 2025 Pullbacks & Verified Momentum Stock Watchlist - newser.com

Oct 22, 2025
pulisher
Oct 22, 2025

Health Canada conditionally approves Gilead Sciences’ Lyvdelzi for PBC - Pharmaceutical Technology

Oct 22, 2025
pulisher
Oct 22, 2025

Is Gilead Sciences Inc. (Common Stock) (GIS0) stock a momentum leaderEarnings Recap Report & Entry Point Confirmation Alerts - newser.com

Oct 22, 2025
pulisher
Oct 21, 2025

Will Gilead Sciences Inc. (Common Stock) (GIS0) stock enhance shareholder value2025 Risk Factors & Reliable Breakout Forecasts - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Will Gilead Sciences Inc. outperform the marketDividend Hike & Daily Volume Surge Trade Alerts - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Why Gilead Sciences Inc. (Common Stock) (GIS0) stock attracts wealthy investorsEarnings Beat & Free Weekly Watchlist of Top Performers - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Will Gilead Sciences Inc. (Common Stock) (GIS0) stock boost dividends furtherMarket Trend Report & Capital Protection Trade Alerts - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Gilead agrees not to raise prices on HIV medicines for state AIDS drug programs - statnews.com

Oct 21, 2025
pulisher
Oct 21, 2025

100 Organizations Denounce Gilead on Price Hikes Gutting ADAP - AIDS Healthcare Foundation

Oct 21, 2025
pulisher
Oct 21, 2025

LYVDELZI® (SELADELPAR) RECEIVES HEALTH CANADA APPROVAL FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS - BioSpace

Oct 21, 2025
pulisher
Oct 21, 2025

LYVDELZI® RECEIVES HEALTH CANADA APPROVAL FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS - Investing News Network

Oct 21, 2025
pulisher
Oct 21, 2025

AHF: 80 Organizations Denounce Gilead on Price Hikes Gutting ADAP - Yahoo Finance

Oct 21, 2025
pulisher
Oct 21, 2025

What makes Gilead Sciences Inc. (Common Stock) (GIS0) stock appealing to growth investorsWeekly Loss Report & Weekly Watchlist of Top Performers - newser.com

Oct 21, 2025
pulisher
Oct 20, 2025

Targets Report: Will Gilead Sciences Inc. (GIS) stock extend growth storyJuly 2025 Chart Watch & Safe Entry Point Alerts - nchmf.gov.vn

Oct 20, 2025
pulisher
Oct 20, 2025

Is Gilead Sciences Inc. stock bottoming outTrade Analysis Summary & AI Enhanced Market Trend Forecasts - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Gilead Sciences (GILD): Assessing Valuation After Major Trodelvy Breast Cancer Breakthrough and HIV Advances - simplywall.st

Oct 20, 2025
pulisher
Oct 20, 2025

Gilead to spotlight new virology data across HIV, viral hepatitis and respiratory diseases at IDWeek 2025 - European AIDS Treatment Group

Oct 20, 2025
pulisher
Oct 20, 2025

How Gilead Sciences Inc. (Common Stock) (GIS0) stock trades after rate cutsEarnings Trend Report & Real-Time Buy Signal Alerts - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Will Gilead Sciences Inc. stock keep outperforming rivalsMarket Growth Summary & Breakout Confirmation Alerts - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Can Gilead Sciences Inc. hit a new high this monthQuarterly Trade Review & Short-Term High Return Strategies - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Will Gilead Sciences Inc. (Common Stock) (GIS0) stock announce a stock splitAnalyst Downgrade & Smart Allocation Stock Tips - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Will Gilead Sciences Inc. (GIS) stock deliver compounding returnsQuarterly Risk Review & Verified Swing Trading Watchlists - nchmf.gov.vn

Oct 20, 2025
pulisher
Oct 20, 2025

Fed Watch: Is Gilead Sciences Inc. (GIS) stock inflation resilientJuly 2025 Earnings & Low Volatility Stock Recommendations - nchmf.gov.vn

Oct 20, 2025
pulisher
Oct 20, 2025

Aug Shorts: Will Gilead Sciences Inc. (Common Stock) (GIS0) stock announce a stock splitJuly 2025 Catalysts & Expert Curated Trade Setup Alerts - nchmf.gov.vn

Oct 20, 2025

Gilead Sciences Inc Azioni (GILD) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$291.76
price down icon 0.39%
drug_manufacturers_general PFE
$24.76
price up icon 0.36%
drug_manufacturers_general SNY
$51.64
price up icon 4.28%
drug_manufacturers_general NVO
$52.96
price down icon 0.51%
drug_manufacturers_general MRK
$87.49
price up icon 0.36%
Capitalizzazione:     |  Volume (24 ore):